| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Neurology, School of Medicine, University of Virginia, Charlottesville, VA (Dr. Dreifuss)
Department of Psychiatry and Behavioral Sciences, University of Health Sciences/Chicago Medical School, North Chicago, IL (Dr. Langer)
Pharmaceutical Products Division, Abbott Laboratories, North Chicago, IL (Dr. Langer, Ms. Moline, and Mr. Maxwell).
We have analyzed the usage pattern of valproate and the associated hepatic fatalities that have been reported in the 2 years since our first study evaluating US experience during the period 1978-1984. In this follow-up study (1985-1986), we have observed a nearly fivefold decrease in the incidence of hepatic fatality during a time when the overall use of valproate has increased significantly. The dramatically decreased incidence, from 0.93 per 10,000 (1/10,000) in 1978–1984 to 0.20 per 10,000 (1/49,000) in 1985-1986 appears to be due to changes in the prescribing patterns of physicians, prompted by greater awareness of low-risk versus high-risk patients. More patients are receiving valproate as monotherapy, considerably more low-risk patients are being treated with valproate, and fewer high-risk patients (0 to 2 years old) are being treated with valproate. During 1985-1986, no hepatic fatalities were reported in any patients above the age of 10 years, regardless of whether valproate was administered as monotherapy or polytherapy. The altered exposure pattern, with an increased use of monotherapy, appears to have had a positive impact on the number of hepatic fatalities (four among 198,000 patients treated during 1985–1986) and contributed to a decreased rate of valproate-associated hepatic fatality.
Address correspondence and reprint requests to Dr. Dreifuss, Department of Neurology, Box 394, University of Virginia Medical Center, Charlottesville, VA 22908.
Received April 12, 1988. Accepted for publication in final form August 16, 1988.
This article has been cited by other articles:
|
|
 |
|
  P. J. Morris Compliance Profile of Depakote ER Compared to Depakote DR and Valproic Acid in Bipolar Patients Journal of Correctional Health Care, October 1, 2008; 14(4): 311 - 317. [Abstract] [PDF]
|
|
|
|
 |
|
 S. A. Hosain, S. Merchant, G. E. Solomon, and A. Chutorian Topiramate for the Treatment of Infantile Spasms J Child Neurol, January 1, 2006; 21(1): 17 - 19. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Sankar Initial treatment of epilepsy with antiepileptic drugs: Pediatric issues Neurology, November 23, 2004; 63(10_suppl_4): S30 - S39. [Abstract] [Full Text]
|
|
|
|
|
|
J. M. Pellock Understanding co-morbidities affecting children with epilepsy Neurology, March 9, 2004; 62(90052): S17 - 23. [Abstract] [Full Text]
|
|
|
|
|
|
D. Hirtz, A. Berg, D. Bettis, C. Camfield, P. Camfield, P. Crumrine, W. D. Gaillard, S. Schneider, and S. Shinnar Practice parameter: Treatment of the child with a first unprovoked seizure: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society Neurology, January 28, 2003; 60(2): 166 - 175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. L. Felker, K. L. Sloan, J. A. Dominitz, and R. F. Barnes The Safety of Valproic Acid Use for Patients With Hepatitis C Infection Am J Psychiatry, January 1, 2003; 160(1): 174 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Shinnar and T. A. Glauser Febrile Seizures J Child Neurol, January 1, 2002; 17(1_suppl): S44 - S52. [Abstract] [PDF]
|
|
|
|
|
|
J. W. Wheless Use of Topiramate in Childhood Generalized Seizure Disorders J Child Neurol, December 1, 2000; 15(1_suppl): S7 - S13. [Abstract] [PDF]
|
|
|
|
 |
|
 K. L. Cozza, E. J. Swanton, and C. W. Humphreys Hepatotoxicity With Combination of Valproic Acid, Ritonavir, and Nevirapine: A Case Report Psychosomatics, October 1, 2000; 41(5): 452 - 453. [Full Text]
|
|
|
|
|
|
S. Hosain, L. Nagarajan, D. Carson, G. Solomon, J. Mast, and D. Labar Felbamate for Refractory Infantile Spasms J Child Neurol, October 1, 1997; 12(7): 466 - 468. [PDF]
|
|
|
|
 |
|
 W. Tang, J. Palaty, and F. S. Abbott Time Course of alpha -Fluorinated Valproic Acid in Mouse Brain and Serum and its Effect on Synaptosomal gamma -Aminobutyric Acid Levels in Comparison to Valproic Acid J. Pharmacol. Exp. Ther., September 1, 1997; 282(3): 1163 - 1172. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. G. Sturgill and G. H. Lambert Xenobiotic-induced hepatotoxicity: mechanisms of liver injury and methods of monitoring hepatic function Clin. Chem., August 1, 1997; 43(8): 1512 - 1526. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Brodie and M. A. Dichter Antiepileptic Drugs N. Engl. J. Med., January 18, 1996; 334(3): 168 - 175. [Full Text] [PDF]
|
|
|
|
|
|
L. J. Willmore, W. J. Triggs, and J. M. Pellock Valproate Toxicity: Risk-Screening Strategies J Child Neurol, January 1, 1991; 6(1): 3 - 6. [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
